Product image of Lapovis (Latanoprost) supplied by GNH India

Lapovis

Active Ingredient:
Latanoprost
Origin:
EU

Lapovis (Latanoprost)

Latanoprost, the active ingredient in Lapovis, is a prostaglandin analog presented as an eye‑drop formulation for ocular use. It is prescribed to lower intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension, thereby helping to preserve visual function. The product meets European Union regulatory standards and is supplied as a prescription‑only medication.

GNH India supplies Lapovis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, eye‑care clinics and procurement teams worldwide, with capabilities for regulated export and quality assurance.

Manufacturer / TM Owner

Zentiva, K.S.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Latanoprost is a prostaglandin analog used to manage conditions characterized by elevated intra‑ocular pressure.
  • Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression.
  • Ocular hypertension: lowers eye pressure to prevent development of glaucoma.
  • Secondary glaucoma (e.g., pseudoexfoliative): helps control pressure when prostaglandin response is appropriate.
  • Normal‑tension glaucoma: provides pressure reduction even within normal range.
  • Post‑surgical ocular hypertension: assists in managing pressure spikes after eye surgery.

How It Works

  • Latanoprost is a synthetic analogue of prostaglandin F2α that binds to FP receptors on the ciliary body epithelium. Activation of these receptors remodels the extracellular matrix, enhancing uveoscleral outflow of aqueous humor. The increased outflow reduces intra‑ocular pressure, providing therapeutic control of glaucoma and ocular hypertension. The effect is dose‑dependent and persists with once‑daily administration, while systemic absorption is minimal.

Side Effects

Latanoprost may cause ocular and systemic adverse reactions, most of which are mild and transient.

Common Side Effects

  • Eye redness: mild conjunctival hyperemia.
  • Eye itching: pruritus of the ocular surface.
  • Increased eyelash growth: longer, thicker lashes.
  • Darkening of iris: gradual brownish pigmentation.
  • Blurred vision: temporary visual disturbance.

Serious or Rare Side Effects

  • Uveitis: inflammation of the uveal tract.
  • Corneal edema: swelling of the cornea.
  • Severe allergic reaction: swelling, rash, or anaphylaxis.
  • Sudden loss of vision: rapid decrease in visual acuity.

Precautions & Warnings

  • Clinicians should consider several precautions before initiating Latanoprost therapy.
  • Pregnancy: safety not established; avoid unless benefit outweighs risk.
  • Breastfeeding: unknown excretion; use with caution.
  • Concomitant ocular inflammation: may exacerbate uveitis; monitor closely.
  • Contact lens wearers: may cause deposits; advise removal before use.
  • Allergy to prostaglandin analogs: contraindicated.
  • Store at room temperature: keep in original container, protect from light and moisture.

Avoid Interactions

Latanoprost can interact with other ocular or systemic agents.

Major Interactions (Avoid)

  • Prostaglandin analog combination: additive pressure‑lowering effect may cause hypotony.
  • Non‑steroidal anti‑inflammatory eye drops: may reduce efficacy.
  • Systemic carbonic anhydrase inhibitors: increased risk of ocular side effects.

Moderate Interactions (Monitor Closely)

  • Beta‑blocker eye drops: additive IOP reduction; monitor pressure.
  • Alpha‑agonist eye drops: potential synergistic effect.
  • Systemic corticosteroids: may diminish prostaglandin response.

Frequently Asked Questions

Lapovis contains latanoprost, a prostaglandin analog indicated for the reduction of intra‑ocular pressure in patients with open‑angle glaucoma and ocular hypertension. By lowering eye pressure, it helps to prevent optic nerve damage and preserve visual function.

Latanoprost mimics prostaglandin F2α and binds to FP receptors in the ciliary body. This triggers remodeling of extracellular matrix proteins, increasing uveoscleral outflow of aqueous humor, which in turn lowers intra‑ocular pressure.

The dosing regimen for Lapovis is determined by the prescribing clinician. In clinical practice it is commonly administered as one drop in the affected eye once daily, usually in the evening, but the exact schedule should follow the prescriber’s instructions.

Safety of latanoprost during pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician.

To order Lapovis, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to latanoprost is the beta‑blocker class, such as timolol. Latanoprost generally offers once‑daily dosing with a favorable side‑effect profile focused on ocular changes, whereas beta‑blockers may cause systemic cardiovascular effects. Choice depends on patient tolerance, comorbidities and physician preference.

Lapovis eye drops should be stored at room temperature, below 25 °C, in the original container. Protect the bottle from light and moisture, and keep the cap tightly closed when not in use to maintain sterility.

Instill one drop of Lapovis into the affected eye(s) as directed by the prescriber, typically in the evening. Avoid touching the tip of the bottle to the eye or any surface to prevent contamination, and wash hands before and after application.

Serious adverse events, although rare, include uveitis, corneal edema, severe allergic reactions, and sudden loss of vision. Patients should seek immediate medical attention if they experience eye pain, redness, vision changes, or any signs of an allergic response.

Lapovis is contraindicated in individuals with known hypersensitivity to latanoprost or any component of the formulation, and it should be used with caution in patients with active ocular inflammation, pregnancy, or breastfeeding until safety is established.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Latanoprost

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT